ERBB2 and neoplasm: 28 tumor samples were obtained from 20 HER2-positive breast cancer patients treated with neoadjuvant therapy: 12 from patients who achieved pathological complete response (pCR) before treatment, and 8 from patients who did not (non-pCR).